Clinical Trial Update: Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating apatinib in combination with S-1 as maintenance therapy for HER-2 negative gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Beijing Hospital | Conditions: HER-2 Negatived Gastric Cancer | Phase 2 | Status: UNKNOWN